GW Pharmaceuticals
private company limited by shares
GW Pharmaceuticals Limited is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.
Source: Wikipedia · CC BY-SA 4.0
last observed
Activity Score
—
not enough monitored evidence
Hiring Momentum 30d
—
not enough monitored evidence
Product Velocity
—
not enough monitored evidence
AI Adoption
—
not enough monitored evidence
Corporate Change Index
—
not enough monitored evidence
5 active sensors·0 observations·0 historical changes·0 structured events
Compare GW Pharmaceuticals with peers on activity, hiring, product velocity, AI adoption, locations and events.
Compare companies
